Abstracts tagged "pain"

Abstract Number: 1794 • ACR Convergence 2025
OA-associated pain sensitivity is reduced in OA-protected MRL/MpJ mice, partially mediated by the gut microbiome, and transferable via microbiome transplantation
Gabriella Dyson¹, Montana Barrett¹, Nicholas Hanebutt¹, Aleksander Szymczak², Cindy Miranda Brawner¹, Pratibha Dube³, Ausitn Lopez¹, Padmaja Mehta-d'Souza¹ and Matlock Jeffries², ¹Oklahoma Medical Research Foundation, Oklahoma City, ²Oklahoma Medical Research Foundation, Oklahoma City, OK, ³Oklahoma Medical Research Foundation, Edmond, OK
Background/Purpose: MRL/MpJ (MRL) mice are protected from developing post-traumatic osteoarthritis (OA) histologic changes. We have previously shown the gut microbiome to play a key role…
Abstract Number: 1289 • ACR Convergence 2025
Longitudinal Exploration of Pain and Disease Characteristics in Youth with Childhood-Onset Lupus
Jida Jaffan¹, Tala El Tal², Lawrence Ng³, Asha Jeyanathan⁴, Hunter Hogarth⁵, Adrienne Davis⁴, Linda Hiraki⁵, Deborah Levy⁵, Zahi Touma⁶, Natoshia Cunningham⁷, Ashley Danguecan⁸ and Andrea Knight⁸, ¹The Hospital for Sick Children/ University of Toronto, Toronto, ON, Canada, ²Children's Hospital of Eastern Ontario (CHEO), Ottawa, ON, Canada, ³The Hospital for Sick Children, Toronto, Canada, Toronto, ON, Canada, ⁴The Hospital for Sick Children, Toronto, Canada, ⁵The Hospital for Sick Children, Toronto, ON, Canada, ⁶University of Toronto, Toronto, ON, Canada, ⁷Michigan State University, Grand Rapids, MI, ⁸Hospital for Sick Children, Toronto, ON, Canada
Background/Purpose: Pain is a common symptom in childhood-onset systemic lupus erythematosus (cSLE) which impacts health-related quality of life. Its relationship to disease measures over time…
Abstract Number: 1233 • ACR Convergence 2025
Synovial Joint Transcriptomic Differences in Individuals with Knee Osteoarthritis and Neuropathic Pain Symptomology
Joseph Lesnak¹, Michael Zuscik², Michael Dayton², Craig Hogan², Prabil Kaini², Andrew Clauw³, Jennifer Seifert⁴, Michael Clay⁵, Theodore Price¹ and Larry Moreland⁶, ¹University of Texas at Dallas, Dallas, ²University of Colorado School of Medicine, Aurora, ³Univ of Colorado, Aurora, CO, ⁴University of Colorado and Oklahoma Medical Research Foundation, Aurora, CO, ⁵University of Colorado, Aurora, CO, ⁶University of Colorado, Denver, CO
Background/Purpose: Osteoarthritis (OA) is a painful disease of the synovial joint and is the most common form of arthritis with a large global burden. A…
Abstract Number: 0644 • ACR Convergence 2025
Improvement of Fatigue, Musculoskeletal Pain, and Morning Stiffness in Patients with Systemic Lupus Erythematosus Treated with Dapirolizumab Pegol: 48-Week Results from a Phase 3 Trial
Ioannis Parodis¹, Caroline Gordon², Joan Merrill³, Matthias Schneider⁴, Zahi Touma⁵, Teri Jimenez⁶, Thomas Morel⁷, Mina Nejati⁸, Christian Stach⁹, Christine de La Loge¹⁰ and Laurent arnaud¹¹, ¹Karolinska Institutet and Karolinska University Hospital, Department of Medicine Solna, Division of Rheumatology, Stockholm, Sweden, ²Department of Inflammation and Ageing, College of Medicine and Health, University of Birmingham, Birmingham, United Kingdom, ³Oklahoma Medical Research Foundation, Oklahoma City ⁷³¹⁰⁴, OK, ⁴Clinic of Rheumatology and Hiller Research Unit, Heinrich-Heine-University, Düsseldorf, Germany, ⁵University of Toronto, Toronto, ON, Canada, ⁶UCB, Raleigh, NC, ⁷UCB, Basel, Switzerland, ⁸Biogen, Cambridge, MA, ⁹UCB, Monheim am Rhein, Germany, ¹⁰UCB, Brussels, Belgium, ¹¹Service de rhumatologie, Hôpitaux Universitaires de Strasbourg, INSERM UMR-S ¹¹⁰⁹, Strasbourg, France, Strasbourg, France
Background/Purpose: Fatigue, musculoskeletal pain, and joint stiffness are common manifestations of SLE, presenting considerable treatment challenges, particularly in addressing chronic fatigue. Dapirolizumab pegol (DZP) is…
Abstract Number: 0386 • ACR Convergence 2025
Introducing the Multidimensional Pain Inventory as a Comprehensive Tool or Assessing Pain in Patients With Axial Spondyloarthritis
David Kiefer¹, Yade Sonkaya², Dietmar Krause³, Markus Voglau⁴, Bernhard Mintrop⁵, Imke Redeker⁶, Xenofon Baraliakos⁷ and Uta Kiltz⁷, ¹Ruhr-Universität Bochum; Private practice of rheumatology, Hattingen, Germany, Herne, Germany, ²Ruhr-Universität Bochum, Herne, Germany, ³Elisabeth-Gruppe, Herne, Germany, Essen, Germany, ⁴myself, Oldenburg, Germany, ⁵Private rheumatology practice, Hattingen, Germany, ⁶Ruhr University Bochum, Bochum, Germany, ⁷Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany
Background/Purpose: The West Haven-Yale Multidimensional Pain Inventory (MPI) is a validated tool designed to assess the multidimensional aspects of chronic pain, including the 5 dimensions…
Abstract Number: 2104 • ACR Convergence 2025
Pain 0-10 visual analog scale (VAS) and RAPID3 (routine assessment of patient index data) in OA and RA are similar in 2024 to 1979 and 1989
Theodore Pincus¹, Tengfei Li² and Juan Schmukler¹, ¹Rush University Medical Center, Chicago, IL, ²Rush, chicago, IL
Background/Purpose: A 1979 report by Huskisson, who developed the 0-10 pain visual analog scale (VAS) , entitled "Another look at osteoarthritis" indicated mean pain VAS…
Abstract Number: 1790 • ACR Convergence 2025
Targeted Ablation of Knee-innervating Nociceptors Attenuates Pain and Cartilage Degeneration in Experimental Osteoarthritis
Lai Wang¹, alia obeidat², Shingo Ishihara³, Jun Li², Frank Ko², Terese Geraghty², Natalie Adamczyk³, Sarah Soorya², Richard Miller⁴, Rachel Miller¹ and Anne-Marie Malfait², ¹Rush University Medical Center, Chicago, IL, ²Rush University Medical Center, Chicago, ³Rush University, Chicago, ⁴Northwestern University, Chicago
Background/Purpose: Nociceptors abundantly innervate the knee joint. In experimental osteoarthritis (OA), nociceptors sprout in the medial synovium and in subchondral bone channels. We aimed to…
Abstract Number: 1278 • ACR Convergence 2025
Differences in Patient and Provider Perception of Functional Status in Adolescents with Lupus
Emily Masi¹, Kimberly Rapoza², Tamar Rubinstein³, Kathy Kenney-Riley⁴ and Joyce Hui-Yuen⁵, ¹Cohen Children's Medical Center, North New Hyde Park, NY, ²Mercy College, Dobbs Ferry, NY, ³Albert Einstein College of Medicine, White Plains, NY, ⁴Mercy University, Dobbs Ferry, NY, ⁵North Shore LIJ Health System, Great Neck, NY
Background/Purpose: Patient and provider discordance can negatively impact medication adherence and disease outcomes in pediatric lupus. Functional status is known to greatly affect perception of…
Abstract Number: 1232 • ACR Convergence 2025
Does Social Support Reduce Bodily Pain among African American Women with SLE?: Findings from a Randomized Controlled Trial
Jerik Leung¹, Tomika Caldwell², Paul Nietert³, Clara Dismuke⁴, Hetlena Johnson⁵, Edith Williams⁶ and Everette Keller³, ¹Emory University, Rollins School of Public Health, Atlanta, GA, ²Medical University of Souty Carolina, Charleston, ³Medical University of South Carolina, Charleston, SC, ⁴VA Palo Alto Health Care System, Menlo Park, ⁵Lupus Community Advocate/Researcher, Columbia, SC, ⁶University of Rochester Medical Center, Rochester, NY
Background/Purpose: Peer mentoring has been shown to be an effective intervention for chronic conditions with evidence to suggest that it might improve health related bodily…
Abstract Number: 0818 • ACR Convergence 2025
Risk of Cardiovascular Events is Higher in Pregabalin Users Versus Duloxetine: A Cohort Study Among Veterans with Chronic Musculoskeletal Pain
Sachalee Campbell¹, Laura Daniel², Puran Nepa², Otis Wilson³, Alyson L. Dickson³, Katherine Murray³, William D. Dupont³, Adriana Hung³, Wayne A. Ray³, Michael Stein⁴ and Cecilia P. Chung², ¹University of Miami, Miami, FL, ²University of Miami, Research Service, Miami VA Healthcare System, Miami, FL, ³Vanderbilt University Medical Center, Vanderbilt, TN, ⁴Vanderbilt University Medical Center, Nashville, TN
Background/Purpose: Pregabalin and duloxetine are among the most prescribed non-opioid medications for patients with chronic pain. Pregabalin may raise the risk for heart failure, and…
Abstract Number: 0332 • ACR Convergence 2025
Safety, Short- and Long-Term Efficacy of Methotrexate in Osteoarthritis: A Systematic Review and Meta-Analysis
Mohamed Abdelsalam¹, Maryam Lasheen², Hadeer Hafez³, Bassant Elaraby Elsayed Badwy⁴, Omar Sameh Nabil El Sedafy¹ and Mohamed Reda Awad⁵, ¹Misr University For Science and Technology, ⁶ october, Al Jizah, Egypt, ²Misr University For Science and Technology, Helwan, Al Qahirah, Egypt, ³⁶th October University, ⁶ october, Al Jizah, Egypt, ⁴Misr University For Science and Technology, Nasr City, Al Qahirah, Egypt, ⁵Al Azhar University, Cairo, Egypt, Giza, Al Jizah, Egypt
Background/Purpose: Methotrexate (MTX), traditionally used for inflammatory conditions like rheumatoid arthritis, has well-established anti-inflammatory properties, recently gained interest as a potential therapeutic option for osteoarthritis…
Abstract Number: 2101 • ACR Convergence 2025
LEVI-04, a Novel Neurotrophin-3 Inhibitor, Demonstrates Clinically Meaningful Improvements in Pain and Physical Function across a Range of OA Outcomes, Including the Staircase-Evoked Pain Procedure (StEPP)
Philip Conaghan¹, nathaniel katz², Asger Bihlet³, Laus W Wullum⁴, Kerry af Forselles⁵, C Michael Perkins⁵, Bernadette Hughes⁶, Claire Herholdt⁷ and Iwona Bombelka⁸, ¹University of Leeds, Leeds, United Kingdom, ²Rin Sof Innovation, Ltd, Boston, MA, ³NBCD A/S, Herlev, Denmark, ⁴Omicron A/S, Copenhagen, Denmark, ⁵Levicept, Sandwich, United Kingdom, ⁶Levicept, Ashtead, United Kingdom, ⁷Levicept Ltd, Ashtead, United Kingdom, ⁸Levicept, Sandwich, Kent, United Kingdom
Background/Purpose: When evaluating new osteoarthritis (OA) therapies, we need to understand their clinical meaningfulness. LEVI-04, a first-in-class p75 neurotrophin receptor-Fc fusion protein that primarily inhibits…
Abstract Number: 1780 • ACR Convergence 2025
Modeling Osteoarthritis Knee Joint in a Compartmentalized Microfluidic System using IPSC-derived Sensory Neurons and human Synovial Fibroblasts
Abdelhak Belmadani¹, Dongjun Ren¹, Daniel Hoffman², Nirupa Jayraj¹, Paola Pacifico¹, Vince Truong³, Patrick Walsh³, Daniela Menichella¹, Anna Rapp⁴, Carla Scanzello⁵, Rachel Miller⁶, Richard Miller⁷ and Anne-Marie Malfait⁸, ¹Northwestern University Chicago, Chicago, IL, ²Rush University, Chicago, IL, ³Anatomic Inc, Minneapolis, MN, ⁴University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, ⁵University of Pennsylvania, Philadelphia, ⁶Rush University Medical Center, Chicago, IL, ⁷Northwestern University, Chicago, ⁸Rush University Medical Center, Chicago
Background/Purpose: Joint pain is one of the most significant clinical hallmarks of knee osteoarthritis (OA). Knee OA is a chronic degenerative disease of the joints…
Abstract Number: 1257 • ACR Convergence 2025
Integrated Behavioral Health Services for Patients with Rheumatic Diseases: Qualitative Analysis of a Pilot Study
Shannon Teaw¹, Jessica Link-Malcolm², Michelle Ghebranious Farag³, Dorothy Patterson², Jenny Foster⁴, Sofia Bereket², Puneet Bajaj², Urooj Wahid², Elizabeth Solow², Jennifer Barton⁵ and Una Makris⁶, ¹UT Southwestern Medical School, Dallas, TX, ²UT Southwestern Medical Center, Dallas, TX, ³McGovern Medical School at UT Houston, Houston, TX, ⁴UT Southwestern Medical Center, Dallas, ⁵VA Portland Health Care System/OHSU, Portland, OR, ⁶UT Southwestern Medical Center and Dallas VA, Dallas, TX
Background/Purpose: Rheumatic diseases (RD) often cause pain, fatigue and disability. Depression and anxiety are prevalent comorbidities in RD and ideally managed with behavioral health (BH)…
Abstract Number: 1230 • ACR Convergence 2025
Chronic pain phenotypes in older adults: Identifying patterns of musculoskeletal pain and associated burden
Gillian Fennell¹, Sarah Tilley², Sayali Dhamne³, Robert Edwards⁴, Mary Gheller³, Angelo Demalia³, Margaret Clancy³, Michael LaValley⁵, Emelia J Benjamin³ and Tuhina Neogi⁶, ¹Boston University Medical, Boston, MA, ²Boston University School of Medicine, Somerville, MA, ³Boston University Chobanian & Avedisian School of Medicine, Boston, MA, ⁴Brigham and Women's Hospital & Harvard Medical School, Boston, MA, ⁵Boston University School of Public Health, Arlington, MA, ⁶Boston University School of Medicine, Boston, MA
Background/Purpose: Over a third of older Americans experience chronic pain, typically occupying multiple musculoskeletal body sites. While number of pain sites (NPS) is often touted…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].